PMID-29998800 – BPC 157 and Standard Angiogenic Growth Factors
Seiwerth S, Rucman R, Turkovic B, Sever M, Klicek R, Radic B, Drmic D, Stupnisek M, Misic M, Vuletic LB, Perovic D, Sikiric P et al. "BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing," Current Pharmaceutical Design, 2018;24(18):1972-1989. doi:10.2174/1381612824666180712110447
Quick Reference
| Property | Value |
|---|---|
| PMID | 29998800 |
| DOI | 10.2174/1381612824666180712110447 |
| Year | 2018 |
| Journal | Current Pharmaceutical Design |
| Study Type | Narrative Review |
| Evidence Level | V |
| Sample | Review of preclinical studies comparing BPC 157 to standard growth factors |
| Peptide(s) Studied | BPC-157 |
Key Findings
- Comprehensive comparison of BPC 157 vs. standard angiogenic growth factors (EGF, FGF, VEGF, PDGF)
- BPC 157 was consistently effective across ALL acute and chronic injury models tested, while standard growth factors showed variable efficacy depending on tissue type
- Unlike growth factors requiring local delivery with carriers/scaffolds, BPC 157 is effective via systemic administration (SubQ, oral, IP)
- BPC 157 demonstrates broader tissue coverage: GI tract, tendons, ligaments, muscle, and bone — whereas individual growth factors tend to be tissue-specific
- Proposes BPC 157 as a "full cytoprotection range" agent that does not require scaffolds or carriers
Study Design
Narrative review comparing the therapeutic profiles of BPC 157 with standard angiogenic growth factors across GI and musculoskeletal healing models. Draws on the Sikiric/Seiwerth group's extensive preclinical database.
Limitations
- Largely based on preclinical animal data
- Comparisons are drawn across different studies rather than head-to-head trials
- Majority of BPC 157 data originates from the authors' own research group (single-group concern)
- No human clinical comparison data available
Clinical Relevance
Positions BPC 157 as a uniquely versatile healing peptide compared to established growth factors. The ability to work systemically without carriers is clinically meaningful if confirmed in human trials. Relevant for practitioners considering BPC-157 vs. PRP or growth factor therapies for tissue repair.
Related
#research #narrative-review #evidence-level-V